Roche's Gazyva shows breakthrough potential in treating lupus patients

Roche's drug Gazyva/Gazyvaro has delivered promising results in treating systemic lupus erythematosus (SLE). The therapy, already used for other conditions, could soon offer a new option for patients with this chronic autoimmune disease. Regulatory submissions are now expected as the company prepares to share the findings with health authorities.

The Allegory trial tested Gazyva/Gazyvaro (obinutuzumab) against standard treatments for SLE. After 52 weeks, more patients on the drug showed improvement in the SLE Responder Index 4 (SRI-4). All secondary goals of the study were also met.

SLE often leads to frequent flare-ups, causing widespread inflammation and organ damage. Around half of those diagnosed develop lupus nephritis—a serious kidney complication—within five years. The disease affects over three million people worldwide, with women of colour aged 15 to 45 at the highest risk.

If approved, Gazyva/Gazyvaro would mark a first for SLE treatment. As an anti-CD20 therapy, it directly targets B cells, which play a key role in the disease. Roche aims to submit the data to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) soon, with potential approvals expected between 2025 and 2026.

The trial results bring hope for a new SLE treatment option. Roche's next steps involve regulatory reviews, which could lead to the first anti-CD20 therapy for the disease. Approval would provide a targeted solution for patients who currently have limited alternatives.